Transthyretin as a Novel Biomarker for Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients

Background: Hepatocellular carcinoma [HCC] is one of the leading causes of cancer-related deaths worldwide. A major problem with HCC surveillance is the lack of reliable biomarkers. Serum transthyretin [TTR] may be a sensitive marker for the diagnosis of patients with liver cell damage, liver cirrho...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Magda Ibrahim, Fathiya El-Raey, Naglaa Fathy, Kadrey El-Bakrey
Formato:	article
Lenguaje:	EN
Publicado:	Al-Azhar University, Faculty of Medicine (Damietta) 2020
Materias:	ttransthyretin cirrhosis hepatocellular carcinoma alpha-fetoprotein noninvasive Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/709c6afa507b4ed8be2a6b9fd04fca2e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:709c6afa507b4ed8be2a6b9fd04fca2e
record_format	dspace
spelling	oai:doaj.org-article:709c6afa507b4ed8be2a6b9fd04fca2e2021-12-02T13:52:45ZTransthyretin as a Novel Biomarker for Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients2636-41742682-378010.21608/ijma.2020.23373.1094https://doaj.org/article/709c6afa507b4ed8be2a6b9fd04fca2e2020-04-01T00:00:00Zhttps://ijma.journals.ekb.eg/article_82380_37df342f1483d981733ec70d834c8af1.pdfhttps://doaj.org/toc/2636-4174https://doaj.org/toc/2682-3780Background: Hepatocellular carcinoma [HCC] is one of the leading causes of cancer-related deaths worldwide. A major problem with HCC surveillance is the lack of reliable biomarkers. Serum transthyretin [TTR] may be a sensitive marker for the diagnosis of patients with liver cell damage, liver cirrhosis or hepatocellular carcinoma. Aim of the work: This study aimed to evaluate the potentiality of serum transthyretin [TTR] as a novel biomarker for detection of HCC in cirrhotic patients. Patients and Methods:This Current study was conducted on 70 patients with chronic liver disease. Also, 20 healthy person matched for age and sex were included as a control group. Patients were classified into 2 groups [30 cirrhotic patients with newly diagnosed HCC & 40 cirrhotic patients without HCC]. Serum TTR levels were measured using enzyme linked immunosorbent assay technique. Results: Serum levels of TTR were significantly much lower in HCC patients when compared to cirrhotic patients without HCC or control group [p<0.0001]. Significant decrease of serum TTR in HCC patients, with portal vein invasion or nodal invasion than in HCC without vascular or nodal invasion. The diagnostic accuracy of TTR was higher than that of AFP regarding sensitivity [83.3%] and negative predictive value [81.4%] in diagnosis of HCC. Conclusion: detection of lower level of TTR alone or in combination with other validated markers may be potentially informative biomarker for detection of HCC among cirrhotic patients at early noninvasive stage where curative treatment can be applied.Magda IbrahimFathiya El-RaeyNaglaa FathyKadrey El-BakreyAl-Azhar University, Faculty of Medicine (Damietta)articlettransthyretincirrhosishepatocellular carcinomaalpha-fetoproteinnoninvasiveMedicine (General)R5-920ENInternational Journal of Medical Arts, Vol 2, Iss 2, Pp 412-419 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	ttransthyretin cirrhosis hepatocellular carcinoma alpha-fetoprotein noninvasive Medicine (General) R5-920
spellingShingle	ttransthyretin cirrhosis hepatocellular carcinoma alpha-fetoprotein noninvasive Medicine (General) R5-920 Magda Ibrahim Fathiya El-Raey Naglaa Fathy Kadrey El-Bakrey Transthyretin as a Novel Biomarker for Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients
description	Background: Hepatocellular carcinoma [HCC] is one of the leading causes of cancer-related deaths worldwide. A major problem with HCC surveillance is the lack of reliable biomarkers. Serum transthyretin [TTR] may be a sensitive marker for the diagnosis of patients with liver cell damage, liver cirrhosis or hepatocellular carcinoma. Aim of the work: This study aimed to evaluate the potentiality of serum transthyretin [TTR] as a novel biomarker for detection of HCC in cirrhotic patients. Patients and Methods:This Current study was conducted on 70 patients with chronic liver disease. Also, 20 healthy person matched for age and sex were included as a control group. Patients were classified into 2 groups [30 cirrhotic patients with newly diagnosed HCC & 40 cirrhotic patients without HCC]. Serum TTR levels were measured using enzyme linked immunosorbent assay technique. Results: Serum levels of TTR were significantly much lower in HCC patients when compared to cirrhotic patients without HCC or control group [p<0.0001]. Significant decrease of serum TTR in HCC patients, with portal vein invasion or nodal invasion than in HCC without vascular or nodal invasion. The diagnostic accuracy of TTR was higher than that of AFP regarding sensitivity [83.3%] and negative predictive value [81.4%] in diagnosis of HCC. Conclusion: detection of lower level of TTR alone or in combination with other validated markers may be potentially informative biomarker for detection of HCC among cirrhotic patients at early noninvasive stage where curative treatment can be applied.
format	article
author	Magda Ibrahim Fathiya El-Raey Naglaa Fathy Kadrey El-Bakrey
author_facet	Magda Ibrahim Fathiya El-Raey Naglaa Fathy Kadrey El-Bakrey
author_sort	Magda Ibrahim
title	Transthyretin as a Novel Biomarker for Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients
title_short	Transthyretin as a Novel Biomarker for Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients
title_full	Transthyretin as a Novel Biomarker for Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients
title_fullStr	Transthyretin as a Novel Biomarker for Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients
title_full_unstemmed	Transthyretin as a Novel Biomarker for Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients
title_sort	transthyretin as a novel biomarker for diagnosis of hepatocellular carcinoma in cirrhotic patients
publisher	Al-Azhar University, Faculty of Medicine (Damietta)
publishDate	2020
url	https://doaj.org/article/709c6afa507b4ed8be2a6b9fd04fca2e
work_keys_str_mv	AT magdaibrahim transthyretinasanovelbiomarkerfordiagnosisofhepatocellularcarcinomaincirrhoticpatients AT fathiyaelraey transthyretinasanovelbiomarkerfordiagnosisofhepatocellularcarcinomaincirrhoticpatients AT naglaafathy transthyretinasanovelbiomarkerfordiagnosisofhepatocellularcarcinomaincirrhoticpatients AT kadreyelbakrey transthyretinasanovelbiomarkerfordiagnosisofhepatocellularcarcinomaincirrhoticpatients
_version_	1718392385918992384

Transthyretin as a Novel Biomarker for Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients

Ejemplares similares